Contact Us Now

(888) 583-9030

• Leadership
• Terms and Conditions
• Advisory Boards
• Regulatory
• Tests Under Development
• Investors

ABOUT US

OUR MISSION: Transforming Discovery into Life-Saving Action

Oncimmune (USA) LLC has a single goal: To advance early cancer detection to the greatest extent possible using autoantibody assay technology through the Early Cancer Detection Test. To achieve this goal, we will strive to:

• Make the test available to at-risk individuals through their health care provider.
• Meet the highest levels of production and laboratory testing standards and ensure we meet or exceed CLIA requirements and standards.
• Continue developing EarlyCDT^TM for a wide range of cancers.
• Support university-based and other research efforts in autoantibody assay technology through The Centre of Excellence for Autoimmunity in Cancer (CEAC) at the University of Nottingham (UK).
• Provide value-added services and information to our clients and cancer advocacy groups to promote and support cancer prevention and early detection.

Early Detection

It is evident through randomized controlled trials of breast, cervical and colorectal cancers that early detection improves prognosis for survival and lowers mortality rates. For other types of cancers such as gastric and lung, additional evidence from nonrandomized studies supports the suggestion that early diagnosis may lead to improved survival. Computerized tomography, CT, studies also confirm that lung cancer patients experience greatly increased survival rates when the cancer is identified at stages I or II. Currently, there is no accepted method of early detection for lung cancer, defined as stage I or II, when time allows for surgical removal with a reasonable chance for a cure (75 percent or higher).

EarlyCDT

In the ongoing effort to improve the outcome of patients diagnosed with cancer, Oncimmune pursues early cancer detection through the biomedical technology initially identified in the laboratories of John Robertson, M.D., professor of surgery at Nottingham University, England, and chief scientific officer of Oncimmune LTD. Oncimmune’s EarlyCDT test has the potential to detect cancer developing in the earliest stages of the disease. Using proprietary immuno-biomarker technology, the test measures a panel of autoantibodies in the patient’s serum. Analyzing more than 80,000 patient samples, Oncimmune has validated the platform and scaled it into a commercial laboratory test. The company has launched its first test, EarlyCDT-Lung^TM, which is an aid to risk assessment and early detection of lung cancer in high-risk individuals.

About Oncimmune

Oncimmune (USA) LLC, founded in 2006, is an industry leader in early cancer detection. Oncimmune LLC is a wholly-owned subsidiary of Oncimmune LTD based in Nottingham, England. The company is committed to advancing early cancer detection through proprietary autoantibody assay technologies based on biological technology initially identified by John Robertson, M.D., professor of surgery at Nottingham University, England, and chief scientific officer of Oncimmune LTD. Ongoing research and development is conducted by Oncimmune under the direction of Dr. Robertson. The company’s mission is to develop early cancer detection tests to identify more than 90 percent of solid-tumor cancers, which make up 70 percent of all cancers including lung, breast, colorectal, prostate, stomach, pancreatic and ovarian. As a lab service, Oncimmune’s metro Kansas City laboratory is CLIA-certified under the Clinical Laboratory Improvements Amendment of 1988. Oncimmune LTD owns a portfolio of patents including No. 7,402,403 and No. 7,205,117.